Study of the influence and cost-effectiveness of roxostat on blood biochemical indexes in hemodialysis patients with renal anemia
Objective To investigate the effect of roxostat on hemodialysis patients with renal anemia.Methods A total of 80 patients with hemodialysis renal anemia were selected from Longchuan County People's Hospital from July 2021 to December 2022 and divided into two groups with 40 cases each by random number table method.The control group was treated with recombinant human erythropoietin injection,and the observation group was treated with roxostat.The therapeutic effect,adverse reactions incidence and cost were compared.The blood biochemical indexes[hemoglobin(Hb),hematocrit(HCT)and erythropoietin(EPO)]levels were determined.The iron metabolism indexes[transferrin(TRF)and ferritin(FER))]levels were detected by automatic biochemical analyzer.Results The effective rate of the observation group was 87.50%(35/40)higher than that of the control group 67.50%(27/40)(P＜0.05).After treatment,the levels of Hb,HCT and EPO in both groups were significantly increased,and the levels in the observation group were higher(P＜0.05).After treatment,TRF levels in both groups were significantly increased,and the observation group was higher,while FER levels in both groups were decreased,and the observation group was lower(P＜0.05).The treatment cost in the observation group was higher than that in the control group(P＜0.05).The incidence of adverse reactions in the observation group was 7.50%lower than that in the control group 25.00%(P＜0.05).Conclusion Although the cost of roxostat is higher for renal anemia in hemodialysis patients,its effect is better,it can improve the anemia condition of patients,promote iron metabolism and has high safety.
NETL
NSTL
万方数据
